Leishmaniasis (Kala-Azar) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Leishmaniasis (Kala-Azar) – Drugs In Development, 2024 report and make more profitable business decisions.
Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen, and fever. Treatment includes anti-parasitic drugs.
The Leishmaniasis (Kala-Azar) drugs in development market research report provide comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Leishmaniasis (Kala-Azar) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 57 molecules, with 26 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Leishmaniasis (Kala-Azar) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Leishmaniasis (Kala-Azar) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Leishmaniasis (Kala-Azar) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Appili Therapeutics IncBacoba AG
Biokawthar Technologies SAS
BioLingus AG
Central Drug Research Institute
Daiichi Sankyo Co Ltd
DetectoGen Inc
Drugs for Neglected Diseases initiative
Eisai Co Ltd
Foundation For Neglected Disease Research
GSK plc
Hospital Universitrio Professor Edgard Santos
Immune Modulation Inc
Impetis Biosciences Ltd
Institut Pasteur Korea
Isfahan University of Medical Sciences
Macrophage Therapeutics Inc
ManRos Therapeutics
Massachusetts College of Pharmacy and Health Sciences
MedC Biopharma Ltd
Molecular Targeting Technologies Inc
Mycosynthetix Inc
Nanomerics Ltd
Novartis AG
Oblita Therapeutics BVBA
Ohio State University
Pai Life Sciences Inc
Pfizer Inc
Pharos iBio Co Ltd
Rakta Therapeutics Inc
Satellos Bioscience Inc
SATT AxLR SAS
St. John's University
Synstar Japan Co Ltd
The Lundquist Institute
University of California San Francisco
University of Dundee
University of Nantes
University of Valencia
University of Washington
University of York
Walter Reed Army Institute of Research
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Leishmaniasis (Kala-Azar) reports